Leukemia: Clinical Trials

389 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

389 completed. 389 Phase 3, 41 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3389Completed 389
Phase 241Completed 41

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 389 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients
Experimental: Venetoclax in combination with Decitabine (+-sorafenib), Active Comparator: Standard dose of Venetoclax + Azacitidine - Elderly AML Patients, Unfit, New-diagnosis AML
Phase 3CompletedThe Second Affiliated Hospital of Kunming Medical University1542023-11-012026-09-09
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
Mesh - spatial repellent impregnated with transfluthrin (2500mg), Information and Education Campaigns (IEC), test and treat malaria cases - Malaria, Childhood ALL
Phase 3CompletedThe Mentor Initiative24002023-06-052024-04-23
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
Azacitidine Combined With Venetoclax and ATRA group - Acute Myeloid Leukemia
Phase 3CompletedThe First Affiliated Hospital of Soochow University602022-10-312026-06-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia
Phase 3CompletedNovartis Pharmaceuticals1992021-10-132026-03-18
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
ABL001 - Chronic Myelogenous Leukemia - Chronic Phase
Phase 3CompletedNovartis Pharmaceuticals562021-05-252025-10-16
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Glasdegib, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 3CompletedPfizer142021-05-172023-12-18
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
Venetoclax, Cytarabine - Acute Myeloid Leukemia (AML)
Phase 3CompletedAbbVie142020-10-052022-05-05
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Phase 3CompletedOctapharma2472020-10-052026-11-02
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes
HCL, verapamil 120mg tablet, non-HCL - Type1 Diabetes
Phase 3CompletedJaeb Center for Health Research1132020-07-092024-11-27
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Obinutuzumab, Venetoclax, Fludarabine - Chronic Lymphocytic Leukemia (CLL)
Phase 3CompletedHoffmann-La Roche1662020-05-282026-03-03
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML)
Phase 3CompletedAbbVie1122020-03-262026-04-08
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
IM JZP-458, IV JZP-458 - Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Phase 2 / Phase 3CompletedJazz Pharmaceuticals2292019-12-272023-11-18
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Acalabrutinib - Chronic Lymphocytic Leukemia
Phase 3CompletedAstraZeneca5522019-09-172026-09-01
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Venetoclax, Azacitidine, Decitabine - Acute Myeloid Leukemia (AML), Cancer
Phase 3CompletedAbbVie602019-08-152023-03-20
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate - Acute Leukemia, Chronic Myelogenous Leukemia (CML)
Phase 3CompletedMedical College of Wisconsin4312019-06-252026-11-16
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
Oral azacitidine, Matched placebo - Acute Myeloid Leukemia, Myelodysplasia
Phase 3CompletedUniversity of Birmingham3262019-06-142026-08-14
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Ruxolitinib - Steroid Refractory GVHD
Phase 3CompletedYi-Lun Wang62019-01-012024-03-05
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
Hizentra - Secondary Immune Deficiency Disorder
Phase 2 / Phase 3CompletedRochester General Hospital202018-11-052020-08-26
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Zanubrutinib, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3CompletedBeiGene6522018-11-012025-03-30
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
G-SCF - Granulocyte Colony-stimulating Factor, Minimal Residual Disease
Phase 2 / Phase 3CompletedNanfang Hospital, Southern Medical University7622018-09-042026-11-12

Showing 20 of 389. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (153)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (111)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (97)  ·  Myelodysplastic Syndromes (61)  ·  Lymphoma (56)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (49)  ·  Lymphoma, Non-Hodgkin (42)  ·  Burkitt Lymphoma (35)  ·  Hodgkin Disease (35)  ·  Leukemia, Myeloid, Chronic-Phase (35)  ·  Lymphoma, Follicular (34)  ·  Lymphoma, Large B-Cell, Diffuse (33)  ·  Lymphoma, Mantle-Cell (32)  ·  Multiple Myeloma (32)

Broader conditions

Hemic and Lymphatic Diseases (389)  ·  Neoplasms by Histologic Type (388)  ·  Hematologic Diseases (385)  ·  Neoplasms (364)  ·  Leukemia, Myeloid (214)  ·  Immune System Diseases (213)  ·  Lymphatic Diseases (205)  ·  Immunoproliferative Disorders (204)  ·  Lymphoproliferative Disorders (196)  ·  Pathological Conditions, Signs and Symptoms (185)  ·  Leukemia, Lymphoid (184)  ·  Pathologic Processes (181)  ·  Disease Attributes (174)  ·  Chronic Disease (168)

Interventions

Cytarabine (99)  ·  Cyclophosphamide (76)  ·  Daunorubicin (58)  ·  Methotrexate (57)  ·  Vincristine (44)  ·  Etoposide (42)  ·  Mercaptopurine (39)  ·  Dexamethasone (38)  ·  Doxorubicin (31)  ·  Asparaginase (29)  ·  fludarabine (29)  ·  Prednisone (28)  ·  Rituximab (28)  ·  pegaspargase (26)  ·  Imatinib Mesylate (25)

Sponsors

Children's Oncology Group (26)  ·  Novartis Pharmaceuticals (18)  ·  Hoffmann-La Roche (12)  ·  National Cancer Institute (NCI) (12)  ·  M.D. Anderson Cancer Center (11)  ·  Fred Hutchinson Cancer Center (9)  ·  German CLL Study Group (9)  ·  St. Jude Children's Research Hospital (9)  ·  European Organisation for Research and Treatment of Cancer - EORTC (8)  ·  AbbVie (7)  ·  Eastern Cooperative Oncology Group (7)  ·  Alliance for Clinical Trials in Oncology (6)  ·  Medical College of Wisconsin (6)  ·  Nanfang Hospital, Southern Medical University (6)  ·  University of Ulm (6)

Countries

United States (210)  ·  Germany (120)  ·  France (105)  ·  Canada (99)  ·  Italy (93)  ·  Australia (81)  ·  United Kingdom (80)  ·  Spain (77)  ·  Belgium (64)  ·  Czechia (57)  ·  Poland (57)  ·  Austria (54)  ·  Russia (46)  ·  Israel (44)  ·  Netherlands (41)

Top investigators

Michael Hallek, MD (6)  ·  Qifa Liu (4)  ·  Mary Horowitz, MD (3)  ·  Mary Horowitz, MD, MS (3)  ·  Alan K. Burnett, MD, FRCP (2)

Results publications

PMID 38620092, PMID 39121442, PMID 37267439, PMID 40266025, PMID 23007406, PMID 24970932, PMID 28751558, PMID 31196847, PMID 31375516, PMID 33131249, PMID 33242441, PMID 35829925, PMID 36184192, PMID 36815378, PMID 37341189, PMID 37890117, PMID 38295280, PMID 38446568, PMID 42085603, PMID 19602710, PMID 20154213, PMID 20625116, PMID 21343560, PMID 21719599, PMID 22649106, PMID 22965967, PMID 23233662, PMID 23620574, PMID 24797299, PMID 24816240, PMID 24916506, PMID 26590194, PMID 26888258, PMID 28273028, PMID 29148893, PMID 29255066, PMID 29284596, PMID 29859851, PMID 29880603, PMID 30337300, PMID 31188727, PMID 31601692, PMID 31612640, PMID 32499241, PMID 32735048, PMID 34596937, PMID 34865212, PMID 35014928, PMID 35235189, PMID 35377947

NIH funding

U10CA098543 (15), 2015 (7), 2016 (7), 2009 (6), 2014 (6), U10CA021115 (6), U10CA095861 (5), 2005 (4), 2008 (4), 2017 (4), 2023 (4), U01HL069294 (4), U10CA032102 (4), U10CA180886 (4), U24CA076518 (4)